Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Long-acting parathyroid hormone receptor agonist rectifies hypocalcemia in autosomal dominant hypocalcemia type 1 mice
Fadil M. Hannan, Mark Stevenson, Taha Elajnaf, Hussam Rostom, Kate E. Lines, Michelle Stewart, Sara Wells, Lee Moir, Thomas J. Gardella, Rajesh V. Thakker
Fadil M. Hannan, Mark Stevenson, Taha Elajnaf, Hussam Rostom, Kate E. Lines, Michelle Stewart, Sara Wells, Lee Moir, Thomas J. Gardella, Rajesh V. Thakker
View: Text | PDF
Research Letter Bone biology Endocrinology

Long-acting parathyroid hormone receptor agonist rectifies hypocalcemia in autosomal dominant hypocalcemia type 1 mice

  • Text
  • PDF
Abstract

Authors

Fadil M. Hannan, Mark Stevenson, Taha Elajnaf, Hussam Rostom, Kate E. Lines, Michelle Stewart, Sara Wells, Lee Moir, Thomas J. Gardella, Rajesh V. Thakker

×

Figure 1

Mineral and bone effects of EPT.

Options: View larger image (or click on image) Download as PowerPoint
Mineral and bone effects of EPT.
(A–D) Blood ionized calcium alterations...
(A–D) Blood ionized calcium alterations in (A) Casr+/+ and (B) Casr+/Nuf mice treated with vehicle and in (C) Casr+/+ and (D) Casr+/Nuf mice treated with 2 nmol/kg EPT. (E–L) Effect of 1–4 nmol/kg EPT on plasma concentrations of (E) adjusted calcium (Adj-calcium), (F) phosphate, (G) magnesium, (H) calcium x phosphate, (I) 1,25(OH)2D, (J) ALP, (K) P1NP, and (L) CTX-1. (M–P) Association of adjusted calcium with (M) 1,25(OH)2D, (N) ALP, (O) P1NP, and (P) CTX-1. (Q–S) FE of (Q) calcium (FECa), (R) magnesium (FEMg), and (S) phosphate (FEPi). (T) BMD of male and female Casr+/Nuf mice treated with vehicle (–) or 2 nmol/kg EPT (+). Mean ± SEM values are shown in the bar charts and scatter plots. Shaded and open bars represent Casr+/+ and Casr+/Nuf mice, respectively. Squares denote male mice; circles denote female mice. *P < 0.05, **P < 0.01, and ***P < 0.001. Two-group comparisons were assessed by 2-tailed Student’s t test and comparison of 3 or more groups by 1-way ANOVA.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts